Biomarker test could cut unnecessary antifungal use in ICU
NCT ID NCT02154178
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether using special fungal markers (biomarkers) could help doctors safely stop antifungal drugs earlier in ICU patients. The goal was to reduce the length of treatment and avoid unnecessary side effects. The study included 110 critically ill adults who needed antifungal therapy for the first time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRITICAL ILLNESS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICU, Salengro Hospital, University Hospital of Lille
Lille, Nord, 59035, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI may predict transfusion needs to shield ICU patients from organ failure
- A simple blood test trend may flag ICU patients at risk
- Could a simple CT scan reveal which ICU cancer patients are at highest risk?
- A gentle touch from family may calm the ICU storm
- Can remote exercise rebuild strength in kids after ICU?
- Fasting in the ICU: a metabolic key to immune response?